Fennec Pharmaceuticals (TSX:FRX) EPS (Basic): C$-0.40 (TTM As of Mar. 2026)

What is Fennec Pharmaceuticals EPS (Basic)?

Fennec Pharmaceuticals TSX:FRX +0.89% 54 EPS (Basic) is C$-0.40 as of Mar. 2026. GuruFocus rates TSX:FRX with a GF Score™ of 54/100 and a GF Value™ of C$14.13 (Fairly Valued). The stock has 2 warning signs investors should review.

Fennec Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was C$0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.40.

Fennec Pharmaceuticals's EPS (Diluted) for the three months ended in Mar. 2026 was C$0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.40.

Fennec Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2026 was C$0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was -0.31.

During the past 3 years, the average EPS without NRI Growth Rate was 31.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 36.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 5.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Fennec Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 75.20% per year. The lowest was -81.00% per year. And the median was 18.30% per year.

Fennec Pharmaceuticals (TSX:FRX) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Fennec Pharmaceuticals EPS (Basic) Related Terms

Fennec Pharmaceuticals EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Fennec Pharmaceuticals's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fennec Pharmaceuticals EPS (Basic) Chart

Fennec Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EPS (Basic)

Get a 7-Day Free Trial

-0.86

-1.22

-0.81

-0.03

-0.47

Fennec Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EPS (Basic)	Get a 7-Day Free Trial															-0.06	-0.15	-0.03	-0.24	0.01

54GF Score

Fennec Pharmaceuticals Inc TSX:FRX

EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Fennec Pharmaceuticals EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Fennec Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-13.438	-	0)	/	28.577
	=	-0.47

Fennec Pharmaceuticals's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(0.276	-	0)	/	34.336
	=	0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.40

Frequently Asked Questions Learn more about EPS (Basic) →

What does a EPS (Basic) of C$-0.40 mean?

Fennec Pharmaceuticals (TSX:FRX) has a EPS (Basic) of C$-0.40 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Fennec Pharmaceuticals and its competitors.

Is Fennec Pharmaceuticals' EPS (Basic) too high?

Fennec Pharmaceuticals' current EPS (Basic) is C$-0.40. Overall, Fennec Pharmaceuticals has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.

How does Fennec Pharmaceuticals' EPS (Basic) compare to VRTX and REGN?

Fennec Pharmaceuticals' EPS (Basic) of C$-0.40 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EPS (Basic) for a Biotechnology company?

A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EPS (Basic) mean?

A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Fennec Pharmaceuticals and its competitors. Fennec Pharmaceuticals's current EPS (Basic) is C$-0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Fennec Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Fennec Pharmaceuticals (TSX:FRX) is currently considered Fairly Valued. The stock's GF Value™ is C$14.13, compared to a current price of C$14.74 — trading 4.3% above its estimated fair value. The current EPS (Basic) is C$-0.40. Fennec Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EPS (Basic) calculated?

EPS (Basic) is calculated from a company's financial statements. For Fennec Pharmaceuticals (TSX:FRX), the current EPS (Basic) is C$-0.40 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fennec Pharmaceuticals (TSX:FRX) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of C$14.74 is trading 4.3% above its estimated GF Value™ of C$14.13. GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.

Key valuation signals for TSX:FRX:

EPS (Basic): C$-0.40
GF Value™: C$14.13 vs. price of C$14.74 (4.3% above fair value)
GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the TSX:FRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fennec Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies NEOE:HELP TSX:EPRX TSX:MSCL TSX:HBP NEOE:ONCO TSXV:SHRX XCNQ:QNTM TSXV:NRX XCNQ:TELI XCNQ:METX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges FENC:USA RV41:Germany

Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709

Website https://www.fennecpharma.com

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

54GF Score

Get the complete analysis for TSX:FRX

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$14.74

Price

C$14.13

GF Value

View TSX:FRX Analysis

See EPS (Basic) data for all stocks →